Combination therapy is not beneficial for certain patients with ovarian cancer
OncLive, MedPage Today highlight UC-led research
OncLive and MedPage Today highlighted research presented by the University of Cincinnati Cancer Center's Thomas Herzog that found a combination therapy of afuresertib and paclitaxel did not lead to better survival outcomes when compared to only treating with paclitaxel in patients with platinum-resistant ovarian cancer.
Afuresertib targets a specific protein called pAKT associated with pathways that support tumor growth, while paclitaxel is a common chemotherapy drug administered to patients with platinum-resistant ovarian cancer.
Herzog presented data from the phase 2 PROFECTA-II/GOG-3044 trial at the 2025 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer. The trial found a median progression-free survival of 4.3 months for patients receiving the combination therapy compared to 4.1 months for those receiving paclitaxel alone.
"Clearly, this was a definitive negative trial for the overall population," said Herzog, MD, a University of Cincinnati Cancer Center member, the Paul and Carolyn Flory Professor in Gynecologic Oncology in the UC College of Medicine and director of UC Health’s Gynecologic Cancer Disease Center. "However, the biomarker data is provocative, but remember, this is hypothesis-generating only, as it's nonanalytic.
“Effective treatments for [platinum-resistant ovarian cancer] remain limited, thus novel agents are needed,” Herzog added. “Biomarker-driven strategies targeting pAKT may refine patient selection and enhance treatment outcomes in [platinum-resistant ovarian cancer]. However, further validation will be required to confirm this biomarker strategy.”
Read the MedPage Today article.
Featured photo at top of Thomas Herzog. Photo provided.
Related Stories
Yes, gas prices will be high this summer
June 17, 2026
WLWT turned to assistant professor-educator at the University of Cincinnati Clermont Seth Powless for a look into how supply chain volatility will keep prices up in the air.
UC Foundation Board of Trustees announces seven new members
June 17, 2026
The University of Cincinnati Foundation is proud to announce that seven dedicated community members are joining its board of trustees. Ray Brooks, CEAS ’83; Chris Carper, A&S ’93; Tim Giglio, Bus ’84; Nandita Jena, A&S '03, Bus '03 and Chris Lewis, MD, Med ’00 will begin their term in October 2026. In addition to this esteemed group, two new student trustees, Case Trokhan, Med ’26 and Joseph Verry, Med ’30 are joining the board.
Rivers expert says satellite technology can help protect drinking water
June 17, 2026
University of Cincinnati environmental engineering professor Dongmei Feng is using satellite remote sensing to study rivers around the world and protect drinking water supplies. As co-lead author of a paper in Nature Water and the recipient of two major federal grants, Feng is developing tools to monitor nutrient pollution and toxic algal blooms from space, with applications for cities like Cincinnati.